Dr Huajie Jin (Lily) is a Senior Lecturer and Deputy Head at King’s Health Economics, located at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London.

She also holds honorary associate professorships at University College London (UCL) and the Shanghai Health Development Research Centre, as well as an adjunct associate professorship at Peking University.

Lily gained her BSc in Medicine from Southeast University (PRC) in 2008 and completed a MSc in International Health Policy (health Economics stream) from LSE in 2009. Following the completion of her MSc, Lily worked on the National Institute for Health and Care Excellence (NICE) clinical guidelines for three years. During this period, Lily was the principal health economist of three NICE clinical guidelines and three NICE Medtech innovation briefings (MIBs).

In 2013, Lily joined King's as Senior Health Economist, whilst working she completed her part time PhD in 2019, which aims to build an individual patient level whole disease model covering the entire care pathway for schizophrenia service in the UK. Her PhD study was awarded “PhD of the year” in the Department of Health Service & Population Research. Lily was appointed as Senior Lecturer in Health Economics in 2021.

Research interests

• Health Technology Assessment
• Cost-effectiveness/utility analysis
• Budget impact analysis
• Cost-of-illness study
• Health economic modelling (e.g., decision tree, Markov model, and discrete event simulation)
• Whole disease modelling
• Trial-based economic evaluation
• Real-world evidence
• Integrating health economics across the lifecycle of healthcare interventions—from early research and clinical development to HTA and post-market evaluation

Lily welcomes PhD applications in applied or methodological health economic evaluation, especially those focused on the role of economics in guiding decisions throughout the development and implementation of healthcare technologies

Teaching

Lily is a PhD supervisor for the following projects:

• Pharmacoeconomic Considerations for Early-Stage Drug R&D Pharmaceutical Management Decision Making
• Cost-effectiveness analysis of a value-based Integrated Practice Unit for adults with cardiometabolic diseases at risk of developing or progressing to a more severe stage of chronic kidney disease in Chile
• Cost of illness study of inflammatory arthritis patients with mental health disorders in the UK
• Cost-effectiveness of cognitive behavioural therapy for children and young people with post-traumatic stress disorder in the UK
• Using Real-World Data to Populate the Whole Disease Model for Schizophrenia

Expertise and public engagement

Honorary appointments

• 2024 – Present: Adjunct Associate Professor, Institute for Global Health and Development, Peking University, P.R. China
• 2023 – Present: Honorary Associate Professor, Division of Psychiatry, UCL
• 2021 – Present: Honorary Associate Professor, Health Technology Assessment Research Department, Shanghai Health Development Research Centre, Shanghai, P.R. China
• 2011–2013: Honorary Research Fellow of the Medical Department, Cardiff University
• 2012–2013: Honorary Research Associate at the Swansea Centre for Health Economics, Swansea university

Public engagement

• 2025 – Present: External Examiner for the MSc Health Economics and Decision Modelling course at the University of Sheffield.
• 2021 – Present: Health economic advisor to the scrutiny panel for planned care in Wales.
• 2013 – Present: Peer view papers for a range of journals, including The Lancet Infectious Disease, The Lancet Global Health, The Lancet Public Health, Bulletin of the World Health Organization, Value in Health and PharmacoEconomics etc.

Selection of recent public presentations

• February 2025. Oral presentation of “Evaluating the Cost-Effectiveness of Digital Breast Tomosynthesis in Routine UK Breast Cancer Screening: Health Economics Analysis Plan for the PROSPECTS Trial”, the Economic Evaluations Alongside Trials & Using Real World Evidence Conference, London, UK.
• September 2024. Oral presentation of “Cost-effectiveness Results of YouScreen”, UK National Screening Committee Adult Reference Group Meeting, London, UK.
• September 2023. Oral presentation of “Cost-effectiveness of Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury – An economic evaluation based on trial data, registry data and economic model”, HECUN workshop, Paris, France.
• September 2023. Oral presentation of “The role of HTA in incentivising innovation in pharmaceutical companies” (virtual), ISPOR China 2023, Xi’an, China.
• September 2023. Oral presentation of “Applications of Whole Disease Modelling” (virtual), webinar, Trinity College Dublin, Dublin, Ireland.
• June 2023. Oral presentation of “Preliminary results of a national expert survey about key issues in the methods and process of Health Technology Assessment in China” (virtual), Peking University, Beijing, China
• December 2021. Oral presentation “Use of Whole Disease Models (WDM) and Pathway Models in Health Economic Research — Benefits and Risks” at Virtual ISPOR Europe 2021, Milan, Italy.
• June 2021. Paper accepted for oral discussion at HESG – “Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies”, online conference, Cambridge, UK.
• June 2021. Oral presentation of “The use and value of Whole Disease Modelling Approach in HTA” at Shanghai HTA centre, online seminar, Shanghai, China.
• November 2020. Oral presentation of spotlight session “Novel Methods for Modelling Treatment Sequencing” at Virtual ISPOR Europe 2020, Milan, Italy.
• August 2020. Oral presentation of “Introducing the Whole Disease Modelling (WDM) Approach Online Seminar” at the Health Intervention and Technology Assessment Program (Hitap) online seminar, Nonthaburi, Thailand.
• January 2020. Oral presentation of the findings of the schizophrenia whole disease model at the Health Economics and Decision Science (HEDS) seminar, the University of Sheffield, Sheffield, UK.
• September 2019. Oral presentation of the findings of the schizophrenia whole disease model at the Health Economics Research Centre (HERC) Seminar Series, University of Oxford, UK.